Eye Disease & Ophthalmology Clinical Trials Update: Week 24, 2026

Published June 12, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

To Evaluate the Efficacy and Safety of N-acetyl Cysteine Administration in Patients With Diabetic Retinopathy

This Phase 4 trial led by Ain Shams University is studying whether N-acetyl cysteine, an oral antioxidant, can safely reduce damage caused by diabetic retinopathy. For patients living with type 2 diabetes, this treatment may offer a new way to protect their eyes from the harmful effects of oxidative stress and blood vessel damage. The trial is currently recruiting in Egypt and focuses on improving vision health through a simple oral medication.

Village-Integrated Eye Worker Trial II

University of California, San Francisco is conducting a community-based screening program that uses advanced imaging technology to detect age-related macular degeneration, diabetic retinopathy, and glaucoma early. This trial aims to help older adults at risk avoid severe vision loss by connecting them to care sooner. The study is recruiting participants in the United States and will follow them for nine years to see how early detection impacts eye health over time.

Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the Eye

This study from Zhongshan Ophthalmic Center in China is testing a smartphone-based artificial intelligence system designed to identify several common eye conditions like cataracts and conjunctivitis. If successful, it could make eye disease screening more accessible, especially for people in areas with limited healthcare resources or internet access. Both medical professionals and non-medical users are being enrolled to help evaluate how this tool works in everyday settings.

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

Ocuphire Pharma’s Phase 2 trial has completed testing an oral drug called APX3330 for diabetic retinopathy and diabetic macular edema. The results, based on over 100 participants in the United States, suggest this medication might provide an easier-to-take treatment option that could improve vision outcomes. This study brings hope for simpler management of diabetic eye conditions that currently require more invasive therapies.

Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT

Researchers at Zhongshan Ophthalmic Center are comparing home-based monitoring with standard hospital visits for patients receiving anti-VEGF treatment for diabetic macular edema. This approach could reduce the need for frequent trips to the hospital without sacrificing the effectiveness of the treatment. The trial is recruiting adults in China and aims to make ongoing eye care more convenient and patient-friendly.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.